Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Free Cash Flow (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Free Cash Flow for 9 consecutive years, with -$10.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Free Cash Flow fell 27.36% year-over-year to -$10.8 million, compared with a TTM value of -$31.3 million through Dec 2025, up 7.97%, and an annual FY2025 reading of -$33.1 million, up 2.83% over the prior year.
  • Free Cash Flow was -$10.8 million for Q2 2025 at VYNE Therapeutics, up from -$11.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$4.8 million in Q4 2022 and bottomed at -$17.5 million in Q3 2021.
  • Average Free Cash Flow over 5 years is -$9.3 million, with a median of -$8.8 million recorded in 2024.
  • The sharpest move saw Free Cash Flow skyrocketed 75.98% in 2021, then crashed 75.18% in 2024.
  • Year by year, Free Cash Flow stood at -$10.0 million in 2021, then surged by 51.98% to -$4.8 million in 2022, then decreased by 6.78% to -$5.1 million in 2023, then tumbled by 75.18% to -$9.0 million in 2024, then decreased by 20.05% to -$10.8 million in 2025.
  • Business Quant data shows Free Cash Flow for VYNE at -$10.8 million in Q2 2025, -$11.5 million in Q1 2025, and -$9.0 million in Q4 2024.